Clearing the Way: Targeted Protein Degradation and Cancer Treatment
Innovative methods to remove harmful proteins open doors for cancer therapies.
Elisabeth Hennes, Belén Lucas, Natalie S. Scholes, Xiu-Fen Cheng, Daniel C. Scott, Matthias Bischoff, Katharina Reich, Raphael Gasper, María Lucas, Teng Teng Xu, Lisa-Marie Pulvermacher, Lara Dötsch, Hana Imrichova, Alexandra Brause, Kesava Reddy Naredla, Sonja Sievers, Kamal Kumar, Petra Janning, Malte Gersch, Peter J. Murray, Brenda A. Schulman, Georg E. Winter, Slava Ziegler, Herbert Waldmann
― 7 min read
Table of Contents
- What is Targeted Protein Degradation?
- How Does it Work?
- The Types of Degraders
- The Challenges Ahead
- Natural Products as a Source of Degraders
- IDO1: A Protein with a Dual Role
- Enter iDegs: A New Class of Degraders
- The Mechanism Behind iDegs
- The Proof is in the Research
- Understanding Ubiquitination: The Key to Degradation
- Pinning Down the E3 Ligase
- A New Strategy for Cancer Treatment
- What's Next for iDegs?
- The Takeaway
- Original Source
In the world of biology, proteins are like tiny machines that perform all sorts of tasks in our cells. They help us grow, digest food, and even fight off illnesses. However, sometimes these protein machines can cause problems, like tumor growth or other diseases. This is where a clever trick called "Targeted Protein Degradation" comes into play. It’s like giving our cells a "delete" button for unwanted proteins.
What is Targeted Protein Degradation?
Targeted protein degradation is a method used to remove specific proteins in the body. Imagine your room is cluttered with things you don’t need. Instead of just hiding them away, you want to get rid of them for good. That’s what targeted protein degradation does for proteins. Scientists can create small molecules, also known as "degraders," that help the body’s own cleanup crew—called E3 Ubiquitin Ligases—find and destroy these unwanted proteins.
How Does it Work?
The mechanism here can be compared to a lock and key. The small molecules (the keys) bind to the protein we want to remove and the E3 ligase (the lock). When they come together, the E3 ligase knows it's time to get to work. It labels the targeted protein for destruction using a process called Ubiquitination. Once a protein is tagged, it heads for the “waste disposal” unit of the cell, known as the proteasome, where it is broken down.
The Types of Degraders
There are two main types of these small molecule degraders: PROTACs and molecular glue degraders (MGDs).
-
PROTACs: These are like fancy shoes that help you run faster. They have two ends: one side sticks to the target protein, while the other side sticks to the E3 ligase. They pull the two together, making it easier for the E3 ligase to do its job.
-
Molecular Glue Degraders (MGDs): Think of these as the friendly magnets that keep things together. They only need to attach to either the target protein or the E3 ligase, but they still manage to bring them close enough for the E3 ligase to start the tagging process.
The Challenges Ahead
While targeted protein degradation sounds fantastic, it does have its bumps in the road. Not every protein is easy to reach, and some proteins just refuse to be targeted by current methods. Additionally, some proteins can change shape or mutate in a way that makes them hard to catch by the E3 ligase, giving them the upper hand. This means researchers need to keep coming up with new ideas and approaches to tackle these challenges.
Natural Products as a Source of Degraders
Interestingly, nature is a treasure trove of potential solutions. Natural products and their modified versions can give us new ideas for creating effective degraders. These substances are originally made by living organisms, and they often have unique properties that can be useful for targeted degradation.
More specifically, researchers have been experimenting with pseudo-natural products. These are essentially like remixing your favorite songs to create something fresh. By combining different natural product fragments in new ways, scientists can create compounds that might work better than the traditional ones.
IDO1: A Protein with a Dual Role
One interesting target for these degraders is an enzyme called IDO1 (indoleamine 2,3-dioxygenase 1). IDO1 helps convert tryptophan, an amino acid, into kynurenine, another molecule that plays a role in immune response. Here’s where the plot thickens: low levels of tryptophan and high levels of kynurenine can lead to issues like reduced immune cell activity, making it easier for tumors to sneak by our immune system’s defenses.
Moreover, recent findings suggest that certain viruses, like the Epstein-Barr virus, can increase the expression of IDO1, further complicating matters. Research into IDO1 inhibitors (molecules that stop IDO1) has been ongoing, but success has been limited. That’s why scientists have turned their attention to targeted degradation of IDO1 as a new strategy.
Enter iDegs: A New Class of Degraders
In the search for effective degradation strategies, researchers stumbled upon a group of compounds known as iDegs. These are pseudo-natural products derived from a compound called (-)-myrtanol. What makes iDegs special? They can both inhibit IDO1 activity and promote its degradation.
Think of iDegs as the superhero pairing of a shield and a sword. They not only stop IDO1 from doing its job, but they also help the body get rid of it altogether. This double-whammy might just be what we need to tackle cancer and diseases linked to IDO1.
The Mechanism Behind iDegs
When iDegs bind to IDO1, they trigger changes in its structure. This change allows for easier tagging by the E3 ligase. In a way, iDegs make IDO1 more noticeable to the body's cleanup crew, ensuring that it gets removed more efficiently.
Researchers tested iDegs in various cell types and found that they could reduce IDO1 levels significantly. This means that not only do iDegs stop IDO1 from working, but they also actively promote its removal.
The Proof is in the Research
In experiments, researchers used a large library of small molecules to find potential candidates for degrading IDO1. They discovered iDeg-1, which effectively reduced kynurenine levels in cells. They confirmed its effectiveness with several different cell lines, showing that iDeg-1 was a potent degrader.
The results were impressive. In time, the IDO1 levels dropped significantly, leading to reduced production of kynurenine. In fact, the researchers observed that after adding iDeg-1, IDO1 protein levels decreased without affecting the production of new IDO1, indicating degradation was at play.
Understanding Ubiquitination: The Key to Degradation
To ensure that iDeg-1 was indeed doing its job, researchers needed to understand the process of ubiquitination better. They found that iDeg-1 induced the addition of ubiquitin molecules to IDO1. This was a critical step because only when a protein is tagged with ubiquitin can it be directed to the proteasome for degradation.
When researchers compared the ubiquitination of IDO1 with and without iDeg-1, they confirmed that iDeg-1 indeed increased ubiquitination. The protein was not just being inhibited; it was being marked for destruction.
Pinning Down the E3 Ligase
The scientists wanted to identify exactly which E3 ligase was responsible for the degradation of IDO1 when targeted by iDegs. Through a series of clever experiments, they pinpointed a specific E3 ligase complex called CRL2KLHDC3. This ligase seemed to play a crucial role in the degradation process, acting as the cleanup crew that removes IDO1 once it has been tagged.
Interestingly, even without the presence of iDegs, it was found that IDO1 is a natural target for CRL2KLHDC3. This means that iDegs enhance or "supercharge" the natural degradation process already at work in the body.
A New Strategy for Cancer Treatment
The exciting part? This approach holds promise for treating cancers and diseases connected to the immune system. While traditional inhibitors just block IDO1, they don't address the underlying issue of excess IDO1 protein levels. By using degraders like iDegs, scientists aim to eliminate IDO1 entirely, which might lead to better treatment outcomes.
The idea is to leverage the body’s natural mechanisms, making it work smarter and more efficiently. Instead of simply putting a sticky note on a protein to say, "Don’t work," we're effectively saying, "You're outta here!"
What's Next for iDegs?
Research is ongoing, and scientists are keen to explore other potential applications for iDegs. Could these compounds be modified for other proteins? Can we use this method against other diseases? The possibilities are vast, and the future looks bright for the field of protein degradation.
The Takeaway
When you boil down all this science mumbo-jumbo, the key message is simple: By using innovative strategies to target and degrade problematic proteins like IDO1, scientists are paving the way for new treatments and breakthroughs in medicine. Who knew we could clean up our cells in such a fascinating way? So, the next time you think about proteins, remember they may be busy working away—but with tools like iDegs, we’ve got our cleaning crew on standby, ready to tackle any unwanted guests!
Original Source
Title: Monovalent Pseudo-Natural Product Degraders Supercharge the Native Degradation of IDO1 by KLHDC3
Abstract: Targeted protein degradation (TPD) modulates protein function beyond inhibition of enzyme activity or protein-protein interactions. Most degrader drugs function by directly mediating proximity between a neosubstrate and hijacked E3 ligase. Here, we identified pseudo-natural products derived from (-)-myrtanol, termed iDegs that inhibit and induce degradation of the immunomodulatory enzyme indoleamine-2,3-dioxygenase 1 (IDO1) by a distinct mechanism. iDegs boost IDO1 ubiquitination and degradation by the cullin-RING E3 ligase CRL2KLHDC3, which we identified to natively mediate ubiquitin-mediated degradation of IDO1. Therefore, iDegs increase IDO1 turnover using the native proteolytic pathway. In contrast to clinically explored IDO1 inhibitors, iDegs reduce formation of kynurenine by both inhibition and induced degradation of the enzyme and, thus, would also modulate non-enzymatic functions of IDO1. This unique mechanism of action may open up new therapeutic opportunities for the treatment of cancer beyond classical inhibition of IDO1.
Authors: Elisabeth Hennes, Belén Lucas, Natalie S. Scholes, Xiu-Fen Cheng, Daniel C. Scott, Matthias Bischoff, Katharina Reich, Raphael Gasper, María Lucas, Teng Teng Xu, Lisa-Marie Pulvermacher, Lara Dötsch, Hana Imrichova, Alexandra Brause, Kesava Reddy Naredla, Sonja Sievers, Kamal Kumar, Petra Janning, Malte Gersch, Peter J. Murray, Brenda A. Schulman, Georg E. Winter, Slava Ziegler, Herbert Waldmann
Last Update: 2025-01-04 00:00:00
Language: English
Source URL: https://www.biorxiv.org/content/10.1101/2024.07.10.602857
Source PDF: https://www.biorxiv.org/content/10.1101/2024.07.10.602857.full.pdf
Licence: https://creativecommons.org/licenses/by/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to biorxiv for use of its open access interoperability.